KKR announced it will acquire Integer Holdings for $5.7 billion in cash, taking the medical device component manufacturer private in a transaction valued at $121 per share—a 24% premium to the thirty-day volume-weighted average. Integer, which manufactures batteries for cardiac devices and components for neurostimulators, generated $1.46 billion in revenue over the trailing twelve months with operating margins near 18%. The deal follows KKR's $13 billion take-private of Envision Healthcare in 2018 and its $2.9 billion acquisition of Avantor's biopharma services unit in 2023, both infrastructure plays beneath the brand layer of healthcare.
Integer holds 65% market share in rechargeable battery systems for implantable cardiac defibrillators and supplies components to Abbott, Boston Scientific, and Medtronic under multi-year contracts that renew through 2027. The company operates 15 manufacturing facilities across the U.S., Europe, and Asia, with 42% of revenue derived from cardiac rhythm management and 31% from neuromodulation. KKR's healthcare strategy head did not disclose debt-to-equity ratios for the transaction, but Integer carried $847 million in net debt as of the most recent quarter, implying an enterprise value near $6.5 billion and a valuation of 4.5x trailing revenue. That multiple sits 18% below the sector median for publicly traded device suppliers, which averaged 5.5x over the past six months.
The transaction removes price discovery from a segment allocators use to gauge supply-chain health in implantables. Integer's quarterly earnings provided forward visibility into device volumes at the three largest cardiac manufacturers, who collectively represent $48 billion in annual device revenue. With Integer private, that data evaporates from public filings. The move also concentrates component supply: KKR now controls Integer and holds a 28% stake in Avantor, creating cross-portfolio exposure to both raw materials and finished sub-assemblies in the medical supply chain. For family offices holding Boston Scientific or Abbott, this reduces the number of independent data points available to model device-volume growth. The deal is structured as an all-cash tender with financing from Barclays and JPMorgan, expected to close in the second half of 2025 pending regulatory clearance.
Operators should track Integer's next two quarterly filings before the deal closes, specifically contract renewals with Abbott and Boston Scientific that come due in Q2 and Q3 2025. Those renewals will surface pricing power—or lack thereof—before the company exits public view. Allocators modeling healthcare infrastructure plays should note that KKR's healthcare private equity fund is raising a targeted $7 billion vehicle, per SEC filings from January, with Integer likely the anchor asset. That fund structure implies a hold period of six to eight years, meaning Integer's margins and contract pricing will optimize for cash generation rather than revenue growth.
The Federal Trade Commission has 90 days from filing to issue a second request, with Barclays expecting clearance by August 2025 absent antitrust concerns. Integer's largest contracts contain change-of-control provisions that allow counterparties to renegotiate pricing within 180 days of a transaction close, a detail that will surface in Boston Scientific's Q3 2025 call.